Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-10-30

FDA Approved: OXERVATE — Supplemental Application (Domp farmaceutici S.p.A.)

View source ↗

Summary

FDA approved a supplemental application for Oxervate (cenegermin-bkbj) submitted by Dompé farmaceutici S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxervate (cenegermin)

Snippet

SUPPL AP for OXERVATE (CENEGERMIN-BKBJ)